Premium GLP-1 support, now with oral GLP-1s
At eMed, explore what’s possible when oral GLP-1 treatment is taken as intended, with expert clinical guidance, structured care, and complete support.
You pay for your meds - the rest is on us.
FDA approved
Shown results of up to 15% weight loss
Injection-free – just one pill a day
Includes the same weight loss ingredients as the injection pen (semaglutide)
Studies show GLP-1s can help people lose 15–20% of their body weight and improve blood sugar and heart health.
But what really matters is how you take it – consistency, adherence, side-effect management, lifestyle support, and accountability over time.
That’s exactly what we want to address at eMed.
eMed plans to conduct an observational study to better understand how adults experience care when prescribed oral GLP-1s through eMed. The study will observe participants over a 12-month period as part of routine clinical care.
There is no cost to participate in the eMed Study Program. If prescribed as part of routine clinical care, participants will only be responsible for the cost of the oral semaglutide medication.
https://www.wegovy.com/obesity/is-wegovy-right-for-me/wegovy-pill-results.html
.png)
GLP-1 treatments have been shown to reduce HbA1c by up to ~1.0–1.5 percentage points in clinical trials.
Source: Jastreboff et al., NEJM 2022; Pratley et al., Lancet 2018
GLP-1 medications have demonstrated improvements in LDL cholesterol and triglycerides compared with placebo.
Source: Nauck & Meier, Lancet Diabetes Endocrinol 2019
Studies show GLP-1 therapy can lead to significant reductions in CRP, a key marker of inflammation.
Source: Hattori et al., Cardiovascular Diabetology 2020
Research shows GLP-1 therapy can reduce liver fat content and improve ALT in people with metabolic dysfunction.
Source: Armstrong et al., Lancet 2016
In long-term studies, GLP-1 receptor agonists have been associated with reduced risk of major cardiovascular events in people with elevated cardiometabolic risk.
Source: Marso et al., NEJM 2016 (LEADER Trial)